Vaccines

Company: Oxford-AstraZeneca

Type: Viral Vector

Number of Doses: 2 doses

Time Between Doses: 4-12 weeks

Ingredients: ChAdOx1-S Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS CoV 2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.

Allergens: PEG (Polyethylene Glycol). For other allergies, please refer to ingredients list.

Side Effects: 

  • Very Common: Arm Pain, Headache, Fatigue, Chills, Joint Pain, Nausea, Muscle Ache.
  • Common: Swelling at Injection Site, Fever, Vomit, Diarrhea, Flu-like Symptoms.
  • Uncommon: Feeling Dizzy, Decreased Appetite, Abdominal Pain, Enlarged Lymph Nodes, Excessive Sweating, Itchy Skin, Rash, Blood Clots (Under Investigation).

Effectiveness:

  • 76% Effectiveness, 99.9% Effectiveness against Hospitalization
  • Against strains: Can neutralize UK variant, but efficacy % might be affected.

Countries approved in: Albania, Angola, Argentina, Australia, Austria, Belgium, Belize, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Darussalam, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Czechia, Côte d’Ivoire, Democratic Republic of the Congo, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Eswatini, Fiji, Finland, France, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guyana, Hungary, Iceland, India, Indonesia, Iran, (Islamic Republic of) Iraq, Ireland, Italy, Jamaica, Jordan, Kenya, Kosovo, Kuwait, Latvia, Lesotho, Libya, Liechtenstein, Lithuania, Luxembourg, Malawi, Malaysia, Mali, Malta, Mauritius, Mexico, Mongolia, Morocco, Netherlands, Nigeria, Norway, Oman, Pakistan, Papua New Guinea, Philippines, Poland, Portugal, Republic of Korea, Republic of Moldova, Romania, Rwanda, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Slovakia, Slovenia, South Sudan, Spain, Sudan, Sweden, Taiwan, Thailand, Timor-Leste, Uganda, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland, Uzbekistan, Vietnam, Yemen, Zambia

Sources:

Company: Moderna

Type: mRNA

Number of Doses: 2

Time between Doses: 4 weeks

Ingredients:

  • Active: Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2, L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80, ethanol, sucrose, sodium chloride, disodium edetate dihydrate, water for injections.
  • Inactive: PEG2000-DMG: 1,1,2-distearoyl-sn-glycero-3- phosphocholine 2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol, Cholesterol, SM-102: heptadecane-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate, Tromethamine, Tromethamine hydrochloride, Acetic acid, Sodium acetate, Sucrose.

Allergens: PEG (Polyethylene Glycol), Polylobate. For other allergies, please refer to ingredients list.

Side Affects: Fatigue, Headache, Muscle Ache, Chills, Fever, Nausea, Arm Pain, Vomit, Diarrhea, Enlarged Lymph Nodes, Swelling at the Injection Site.

Effectiveness:

  • 94.1% effective
  • 99.9% effective against hospitalization

Countries Approved In: Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czechia, Denmark, Estonia, Faroe Islands, Finland, France, Germany, Greece, Greenland, Guatemala, Honduras, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Mongolia, Netherlands, Norway, Philippines, Poland, Portugal, Qatar, Romania, Rwanda, Seychelles, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland, United States of America, West Bank

Sources:

Company: Pfizer-BioNTech

Type: mRNA

Number of Doses: 2

Time between Doses: 3weeks

Ingredients:

  • Active: Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2.
  • Inactive: 2[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3- phosphocholine, Cholesterol, (4-hydroxybutyl)azanediyl)bis(hexane-6,1- diyl)bis(2-hexyldecanoate), Sodium chloride, Monobasic potassium phosphate, Potassium chloride, Dibasic sodium phosphate dihydrate, Sucrose.

Allergens: PEG (Polyethylene Glycol). For other allergies, please refer to ingredients list.

Side Affects: Fatige, Headache, Muscle Ache, Chills, Fever, Nausea, Arm Pain, Vomit, Diarrhea, Enlarged Lymph Nodes, Swelling at the Injection Site.

Effectiveness:

  • 95.0% effective
  • 99.9% effective against hospitalization

Countries Approved In: Albania, Argentina, Australia, Austria, Bahrain, Belgium, Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Czechia, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Faroe Islands, Finland, France, Germany, Greece, Greenland, Hong Kong, Hungary, Iceland, Iraq, Ireland, Israel, Italy, Japan, Jordan, Kuwait, Latvia, Lebanon, Liechtenstein, Lithuania, Luxembourg, Malaysia, Maldives, Malta, Mexico, Monaco, Mongolia, Netherlands, New Zealand, North Macedonia, Norway, Oman, Panama, Peru, Philippines, Poland, Portugal, Qatar, Republic of Korea, Republic of Moldova, Romania, Rwanda, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Tunisia, Turkey, Ukraine, Ukraine, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland, United States of America, Uruguay, Vatican, West Bank

Sources:

 

 

Company: Johnson and Johnson’s Janssen

Type: viral vector

Number of Doses: 1

Time between Doses: n/a

Ingredients:

  • Active: Recombinant, replicationincompetent Ad26 vector, encoding a stabilized variant of the SARS-CoV-2 Spike (S) protein.
  • Inactive: Polysorbate-80, 2-hydroxypropyl-β-cyclodextrin, Citric acid monohydrate, Trisodium citrate dihydrate, Sodium chloride, Ethanol.se refer to ingredients list.

Side Affects: Fatige, Headache, Muscle Ache, Chills, Fever, Nausea, Arm Pain, Vomit, Diarrhea, Enlarged Lymph Nodes, Swelling at the Injection Site.

Effectiveness:

  • 66.3% effective
  • 99.9% effective against hospitalization

Countries Approved In: Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Colombia, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Philippines, Poland, Portugal, Republic of Korea, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, United States of America, Zambia

Sources:

 

 

Company: Bharat Biotech

Type: inactivated

Number of Doses: 2

Time between Doses: 4 weeks

Ingredients:

  • 6µg of whole-virion inactivated SARSCoV-2 antigen (Strain: NIV-2020-770), and the other inactive ingredients such as aluminum hydroxide gel (250 µg), TLR 7/8 agonist (imidazoquinolinone) 15 µg, 2-phenoxyethanol 2.5 mg, and phosphate buffer saline up to 0.5 ml. COVAXIN has been developed by using inactivated/killed virus along with the aforementioned chemicals.. For other allergies, please refer to ingredients list.

Allergens: Refer to ingredient list

Side Affects: Injection site pain and swelling, body ache, headache, fever, nausea, rashes, vomiting, weakness in injection arm

Effectiveness:

  • 81.0% effective
  • 99.9% effective against hospitalization

Countries Approved In: Guyana, India, Iran (Islamic Republic of), Mauritius, Mexico, Nepal, Paraguay, Philippines, Zimbabwe

Sources:

Company: Sinopharm

Type: inactivated

Number of Doses: 2

Time between Doses: 3-4 weeks

Ingredients:

  • Information not publically available 

Allergens: Information not publically available 

Side Affects:

  • Very Common: Headache.
  • Common: Flushing, Swelling, Scleroma, Rash, Itchy Skin, Fever, Fatigue, Muscle Ache, Joint Paint, Cough, Difficulty Breathing, Nausea, Diarrhea.
  • Uncommon: Erythema, Feeling Dizzy, Decreased Appetite, Vomit, Constipation, Hypersensitivity, Sore Throat, Rhinorrhea.
  • Rare: Acute Allergic Reaction, Lethargy, Drowsiness, Insomnia, Nasal Congestion, Sneezing, Influenza, Hypoesthesia, Limb Pain, Palpitations, Stomach Ache, Abnormal Skin and Mucosa, Acne, Eye Pain, Ear Discomfort, Enlarged Lymph Nodes.
  • Very Rare: Chills, Tremor, Dysgeusia, Difficulty Paying Attention, Nose Bleeds, Asthma, Tonsillitis, Jaw Pain, Neck Lumps, Mouth Ulcers, Toothache, Esophageal Disease, Gastritis, Discoloration of Stool, Blurred Vision, Eye Irritation, Vision Loss, Nervouseness, High Blood Pressure, Low Blood Pressure, Urine Incontinence, Delayed Menstruation.

Effectiveness:

  • 79.3% effective
  • no data on effectiveness against hospitalization

Countries Approved In: Argentina, Bahrain, Bangladesh, Belarus, Bolivia (Plurinational State of), Brunei Darussalam, Cambodia, Cameroon, China, Comoros, Egypt, Equatorial Guinea, Gabon, Guyana, Hungary, Iran (Islamic Republic of), Iraq, Jordan, Kyrgyzstan, Lao People’s Democratic Republic, Lebanon, Maldives, Mongolia, Montenegro, Morocco, Mozambique, Namibia, Nepal, Niger, North Macedonia, Pakistan, Peru, Republic of the Congo, Senegal, Serbia, Seychelles, Sierra Leone, Somalia, Sri Lanka, United Arab Emirates, Venezuela (Bolivarian Republic of), Zimbabwe

Sources:

Company: Gamaleya Institute

Type: Viral vector

Number of Doses: 2

Time between Doses: 3-8weeks

Ingredients:

  • Active: Modified replication-defective adenovirus of a different serotype (Serotype 26 for the first component and serotype 5 for the second), which has been modified to include the protein S-expressing gene of SARS-CoV-2.
  • Inactive: Tris-(hydroxymethyl)-aminomethane, Sodium chloride, Sucrose, Magnesium chloride hexahydrate, Disodium EDTA dihydrate, Polysorbate 80, Ethanol, and Water.

Allergens: Polysorbate, refer to ingredient list for other allergens

Side Affects: Fatigue, Headache, Muscle Ache, Chills, Fever, Nausea, Arm Pain, Swelling at the Injection Site.

Effectiveness:

  • 91.6% effective
  • 99.9% effective against hospitalization

Countries Approved In: Albania, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Azerbaijan, Bahrain, Bangladesh, Belarus, Bolivia (Plurinational State of), Bosnia and Herzegovina, Cameroon, Djibouti, Egypt, Gabon, Ghana, Guatemala, Guinea, Guyana, Honduras, Hungary, India, Iran (Islamic Republic of), Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Lao People’s Democratic Republic, Lebanon, Libya, Mali, Mauritius, Mexico, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nepal, Nicaragua, North Macedonia, Pakistan, Panama, Paraguay, Philippines, Republic of Moldova, Republic of the Congo, Russian Federation, Saint Vincent and the Grenadines, San Marino, Serbia, Seychelles, Slovakia, Sri Lanka, Syrian Arab Republic, Tunisia, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela (Bolivarian Republic of), Viet Nam, West Bank, Zimbabwe

Sources:

Company: Sionvac Biotech

Type: inactivated

Number of Doses: 2

Time between Doses: 4 weeks

Ingredients:

  • Inactivated SARS-CoV-2 Virus (CZ02 strain), aluminum hydroxide, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate monohydrate, and sodium chloride.

Allergens: Refer to ingredient list

Side Affects:

  • Very Common: Arm Pain, Headache, Fatigue.
  • Common: Chills, Nausea, Muscle Ache, Joint Pain, Swelling at Injection Site, Diarrhea, Flu-like Symtpoms, Cough, Rash, Decreased Appetite, Itchy Skin, Rhinorrhea, Sore Throat, Nasal Congestion, Abdominal Pain.
  • Uncommon: Burn at Injection Site, Vomit, Fever, Hypersensitivity, Abnormal Skin and Mucosa, Tremor, Flushing, Edema, Drowsiness, Feeling Dizzy.
  • Rare: Muscle Spams, Eyelid Edema, Nosebleeds, Abdominal Distension, Constipation, Hyposmia, Ocular Congestion, Hot Flashes, Hiccup, Conjuctival Congestion.

Effectiveness:

  • 50.6-83.5% effective
  • 99.9% effective against hospitalization

Countries Approved In: Albania, Azerbaijan, Brazil, Cambodia, Chile, China, Colombia, Dominican Republic, Ecuador, Egypt, El Salvador, Hong Kong, Indonesia, Lao People’s Democratic Republic, Malaysia, Mexico, Pakistan, Panama, Philippines, Thailand, Tunisia, Turkey, Ukraine, Uruguay, Zimbabwe

Sources:

Company: CanSino Biologics

Type: Viral Vector 

Number of Doses: 1

Time between Doses: N/A

Ingredients:

  • Information not publically available 

Allergens: Information not publically available 

Side Affects: n/a

Effectiveness:

  • 65.7% effective
  • no data on effectiveness against hospitalization

Countries Approved In: Chile, China, Hungary

Sources:

Company: Novavax

Type: Protein Subunit

Number of Doses: 2

Time between Doses: 3 weeks

Ingredients:

  • n/a

Allergens: n/a

Side Affects: n/a

Effectiveness:

  • n/a

Countries Approved In: Vaccine currently in testing

Sources:

Company: CureVac N.V.

Type: mRNA

Number of Doses: 2

Time between Doses: 4weeks

Ingredients:

  • n/a

Allergens: n/a

Side Affects: n/a

Effectiveness:

  • n/a

Countries Approved In: Vaccine currently in testing

Sources:

Company: Vektor State Research Center of Virology and Biotechnology

Type: Protein Subunit

Number of Doses: 2

Time between Doses: 2-4 weeks

Ingredients:

  • n/a

Allergens: n/a

Side Affects: n/a

Effectiveness:

  • n/a

Countries Approved In: Vaccine currently in testing

Sources:

Company: Chumakov Center

Type: Inactivated

Number of Doses: 2

Time between Doses: 2 weeks

Ingredients:

  • n/a

Allergens: n/a

Side Affects: n/a

Effectiveness:

  • n/a

Countries Approved In: Vaccine currently in testing

Sources:

Company: Serum Institue of India

Type: Viral Vector

Number of Doses: 2

Time between Doses: 4-12 weeks

Ingredients:

  • ChAdOx1-S Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS CoV 2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.

Allergens: PEG (Polyethylene Glycol). For other allergies, please refer to ingedients list

Side Affects:

  • Very Common: Arm Pain, Headache, Fatigue, Chills, Joint Pain, Nausea, Muscle Ache.
  • Common: Swelling at Injection Site, Fever, Vomit, Diarrhoea, Flu-like Symtpoms.
  • Uncommon: Feeling Dizzy, Decreased Appetite, Abdominal Pain, Enlarged Lymph Nodes, Excessive Sweating, Itchy Skin, Rash, Blood Clots (Under Investigation).

Effectiveness:

  • 76% effective
  • 99.9% effective against hospitalization

Countries Approved In:

Albania, Angola, Argentina, Australia, Austria, Belgium, Belize, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Darussalam, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Czechia, Côte d’Ivoire, Democratic Republic of the Congo, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Eswatini, Fiji, Finland, France, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guyana, Hungary, Iceland, India, Indonesia, Iran, (Islamic Republic of) Iraq, Ireland, Italy, Jamaica, Jordan, Kenya, Kosovo, Kuwait, Latvia, Lesotho, Libya, Liechtenstein, Lithuania, Luxembourg, Malawi, Malaysia, Mali, Malta, Mauritius, Mexico, Mongolia, Morocco, Netherlands, Nigeria, Norway, Oman, Pakistan, Papua New Guinea, Philippines, Poland, Portugal, Republic of Korea, Republic of Moldova, Romania, Rwanda, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Slovakia, Slovenia, South Sudan, Spain, Sudan, Sweden, Taiwan, Thailand, Timor-Leste, Uganda, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland, Uzbekistan, Vietnam, Yemen, Zambia

 

Sources: